Unstable angina non ST elevation myocardial infarction aspirin therapy

Jump to navigation Jump to search


Resident
Survival
Guide

Acute Coronary Syndrome Main Page

Unstable angina / NSTEMI Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Unstable Angina
Non-ST Elevation Myocardial Infarction

Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders

Epidemiology and Demographics

Risk Stratification

Natural History, Complications and Prognosis

Special Groups

Women
Heart Failure and Cardiogenic Shock
Perioperative NSTE-ACS Related to Noncardiac Surgery
Stress (Takotsubo) Cardiomyopathy
Diabetes Mellitus
Post CABG Patients
Older Adults
Chronic Kidney Disease
Angiographically Normal Coronary Arteries
Variant (Prinzmetal's) Angina
Substance Abuse
Cardiovascular "Syndrome X"

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Blood Studies
Biomarkers

Electrocardiogram

Chest X Ray

Echocardiography

Coronary Angiography

Treatment

Primary Prevention

Immediate Management

Anti-Ischemic and Analgesic Therapy

Cholesterol Management

Antitplatelet Therapy

Antiplatelet therapy recommendations
Aspirin
Thienopyridines
Glycoprotein IIb/IIIa Inhibitor

Anticoagulant Therapy

Additional Management Considerations for Antiplatelet and Anticoagulant Therapy

Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS

Mechanical Reperfusion

Initial Conservative Versus Initial Invasive Strategies
PCI
CABG

Complications of Bleeding and Transfusion

Discharge Care

Medical Regimen
Post-Discharge Follow-Up
Cardiac Rehabilitation

Long-Term Medical Therapy and Secondary Prevention

ICD implantation within 40 days of myocardial infarction

ICD within 90 days of revascularization

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Unstable angina non ST elevation myocardial infarction aspirin therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Unstable angina non ST elevation myocardial infarction aspirin therapy

CDC onUnstable angina non ST elevation myocardial infarction aspirin therapy

Unstable angina non ST elevation myocardial infarction aspirin therapy in the news

Blogs on Unstable angina non ST elevation myocardial infarction aspirin therapy

to Hospitals Treating Unstable angina non ST elevation myocardial infarction aspirin therapy

Risk calculators and risk factors for Unstable angina non ST elevation myocardial infarction aspirin therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.; Smita Kohli, M.D.

Overview

Antiplatelet therapy plays a major role in the management of unstable angina/NSTEMI. This class of medication is directed towards one of the following three pathways: decreasing thromboxane A2 formation (aspirin), inhibiting the P2Y12 component of the adenosine diphosphate (ADP) receptor pathway (thienopyridines) and direct inhibition of platelet aggregation (GP IIb/IIIa inhibitors).

Aspirin

Mechanism of Benefit

  • One of the medications which has consistently been shown to reduce mortality in ACS or CAD patients is aspirin.

Clinical Trial Data

Until recently, no trial had directly compared the efficacy of different doses of ASA in patients who present with unstable angina/NSTEMI.

  • CURRENT OASIS 7 trial, which was a randomized, multicenter, multinational trial enrolling 25,087 patients with ACS showed no difference in cardiovascular outcomes of death from MI or stroke between low dose aspirin (75-100mg) compared to high dose aspirin (300-325mg) at the end of 30 days.
  • The Second International Study of Infarct Survival (ISIS-2) trial[1] led to the recommendation that ASA be initiated immediately in the emergency room once the diagnosis of ACS is made or suspected. Aspirin therapy can also be initiated in the prehospital setting when ACS is suspected.
  • In regards to safety (e.g., gastrointestinal bleeding), a few large observational studies have found that the rate of bleeding appears to be lower with low-dose aspirin (75-100mg daily) when compared with high dose aspirin (325 mg daily) in patients receiving medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

Dosing

  • Non enteric coated formulations are preferred due to rapid buccal absorption.
  • On the basis of previous randomized trials, the current recommendation for initial dose of aspirin is 162-325mg.
  • After an initial loading dose of 162 to 325 mg, a dose of 75 to 100mg daily appears sufficient.
  • On the basis of current available data, lifelong continuation of aspirin should be encouraged unless contraindicated.
  • In patients who have an allergy or who cannot tolerate aspirin, use of clopidogrel is recommended.

References

  1. "Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group". Lancet. 2 (8607): 349–60. 1988. PMID 2899772. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)

Template:WH Template:WS